Back to results
US 9,753,043 B2Granted
Methods and algorithms for aiding in the detection of cancer
Assignee20/20 GeneSystems, Inc.
InventorsMichael Lebowitz, Ronald Shore
Life of this patent
Estimating the term…
Abstract
A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject.
Claims22
A method comprising:
- a) obtaining a sample from a human subject asymptomatic for lung cancer;
- b) measuring a panel of markers in the sample, wherein at least two of the markers are selected from CEA, CA125, Cyfra 21-1, Pro-GRP, anti-NY-ESO-1, anti-p53, anti-Cyclin E2 and anti-MAPKAPK3;
- c) determining a multiple of median (MoM) score for each marker;
- d) summing the MoM score to obtain a composite score for each human subject, quantifying the increased risk for the presence of lung cancer for the human subject as a risk score, wherein the composite score is matched to a risk category of a grouping of stratified human subject populations wherein each risk category comprises a multiplier indicating increased likelihood of having the lung cancer correlated to a range of composite scores as compared to use of a single threshold value, wherein the multiplier is determined from positive predictive scores of retrospective samples;
- and,
- e) administering a computerized tomography (CT) scan to the human subject with a quantified increased risk for the presence lung cancer.
3 more elements
A method comprising:
- a) obtaining a sample from a human subject asymptomatic for lung cancer, wherein the human subject is at least 50 years of age or older and has a history of smoking tobacco;
- b) measuring at least two cancer marker in the sample wherein the at least two cancer markers are selected from CEA, CA125, Cyfra 21-1, Pro-GRP, anti-NY-ESO-1, anti-p53, anti-Cyclin E2 and anti-MAPKAPK3;
- c) determining a multiple of median (MoM) score for each marker measured in the sample;
- d) summing the MoM score to obtain a composite score for each human subject, quantifying the increased risk for the presence of lung cancer for the human subject as a risk score, wherein the composite score is matched to one of at least three risk categories of a grouping of stratified human subject populations wherein each risk category comprises a multiplier indicating increased likelihood of having the lung cancer correlated to a range of composite scores as compared to use of a single threshold value, wherein the multiplier is determined from positive predictive scores of retrospective samples;
- and,
- e) administering a computerized tomography (CT) scan to the human subject with a quantified increased risk for the presence lung cancer.
3 more elements
Dependencies are inferred from the claim text.